Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.

@article{Fonsart2017SingledosePA,
  title={Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.},
  author={Julien Fonsart and Sentob Saragosti and Milad Taouk and Gilles Peytavin and Lane R. Bushman and Isabelle Charreau and Allan J. Hance and Lauriane Goldwirt and St{\'e}phane Morel and Fabrizio Mammano and B{\'e}n{\'e}dicte Loze and Catherine Capitant and François Clavel and Nadia Mahjoub and Laurence Meyer and Peter L. Anderson and Constance Delaugerre and Jean Michel Molina},
  journal={The Journal of antimicrobial chemotherapy},
  year={2017},
  volume={72 2},
  pages={478-485}
}
OBJECTIVES In the ANRS IPERGAY pre-exposure prophylaxis (PrEP) trial, a single dose of tenofovir disoproxil fumarate and emtricitabine was taken orally 2-24 h before sexual intercourse. A sub-study was conducted to assess the pharmacokinetics of tenofovir and emtricitabine in blood, saliva and rectal tissue following this initial oral intake. METHODS Plasma, PBMC, saliva and rectal tissue sampling was performed over 24 h in 12 seronegative men before enrolment in the ANRS IPERGAY trial… CONTINUE READING